Effects of probiotics, prebiotics and synbiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

Yanyan Tian^{^a}, Jiayue Xia^{^a}, Lihua Li^{^b}, Ligang Yang^{^a}(), Hua Xiao^{^c}, Guoping Gao^{^c}, Yuanyuan Wang^{^a}, Chen Zhang^{^a}, Tiange Bu^{^d}, Guiju Sun^{^a}()

Key Laboratory of Environmental Medicine and Engineering of Ministry of Education, Department of Nutrition and Food Hygiene, School of Public Health, Southeast University, Nanjing 210009, China

Lianshui People’s Hospital Affiliated to Kangda College of Nanjing Medical University, Huai’an 223400, China

Gong’an County People’s Hospital, Jingzhou 434300, China

Department of Nutritional Sciences, University of Toronto, Toronto M5S 1A1, Canada

Peer review under responsibility of Beijing Academy of Food Sciences.

Show Author Information

Abstract

A systematic review and meta-analysis study was conducted to assess the effectiveness of probiotic/prebiotic/synbiotic supplementation on the effects of cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM) based on data from randomized controlled trials (RCTs). We searched electronic databases including PubMed, Cochrane Library, Embase, and Web of Science to identify clinical trials published up to 31 March 2023. Data was pooled using a random-effects model if significant heterogeneity (I² > 50%), otherwise use a fixed-effects model. Fifty-six trials that included 3317 patients were enrolled for analysis. Meta-analysis reported that probiotic/prebiotic/synbiotic supplementation significantly reduced systolic blood pressure (SBP) (weighted mean difference (WMD): −3.57 mmHg, 95% confidence interval (CI): −5.36, −1.78; P = 0.000), diastolic blood pressure (DBP) (WMD: −2.05 mmHg, 95% CI: −3.07, −1.04; P = 0.000), triglycerides (TG) (WMD: −16.10 mg/dL, 95% CI: −20.16, −12.05; P = 0.000), total cholesterol (TC) (WMD: −14.00 mg/dL, 95% CI: −20.46, −7.55; P = 0.000), low-density lipoprotein cholesterol (LDL-C) (WMD: −7.03 mg/dL, 95% CI: −9.25, −4.81; P = 0.000), fasting plasma glucose (FPG) (WMD: −16.57 mg/dL, 95% CI: −20.39, −12.74; P = 0.000), hemoglobin A1c (HbA1c) (WMD: −0.44%, 95% CI: −0.68, −0.20; P = 0.000), insulin (standardized mean difference (SMD): −0.37, 95% CI: −0.53, −0.21; P = 0.000), homeostatic model assessment of insulin resistance (HOMA-IR) (WMD: −1.05, 95% CI: −1.56, −0.54; P = 0.000), C-reactive protein (CRP) (SMD: −0.35, 95% CI: −0.57, −0.13; P = 0.002), tumor necrosis factor-α (TNF-α) (SMD: −1.07, 95% CI: −1.57, −0.56; P = 0.000), interleukin-6 (IL-6) (SMD: −0.37, 95% CI: −0.61, −0.13; P = 0.003) levels, they also increased the high-density lipoprotein cholesterol (HDL-C) (WMD: 3.70 mg/dL, 95% CI: 1.80, 5.60; P = 0.000) levels in T2DM patients, as compared to the placebo groups. This meta-analysis supports the use of probiotic/prebiotic/synbiotic supplementation as an adjunctive therapy to improve blood pressure, glycemic control parameters, lipid profile and inflammatory markers in patients with T2DM, which are well-known cardiovascular risk factors.

Keywords

Probiotic Prebiotic Synbiotic Type 2 diabetes mellitus Cardiovascular risk factors Systematic review and meta-analysis

Electronic Supplementary Material

Download File(s)

fshw-14-1-9250002_ESM.doc (4 MB)

References

[1]

M.A. Nauck, J. Wefers, J.J. Meier, Treatment of type 2 diabetes: challenges, hopes, and anticipated successes, Lancet Diabetes Endocrinol. 9 (2021) 525-544. http://doi.org/10.1016/s2213-8587(21)00113-3.

	1	2
Version 1 Review comment

Effects of probiotics, prebiotics and synbiotics supplementation on cardiovascular risk factors in patients with type 2 diabetes mellitus: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

Abstract

Keywords

Electronic Supplementary Material

References

Review close

Comments on this article

< Back to all reports

Review Comment